South San Francisco-based Veracyte has filed for an IPO, saying that it is looking to raise up to $74.75M in its initial public offering. The company says it plans to debut on the NASDAQ Global Market as VCYT. The company's IPO is being underwritten by Morgan Stanley, Leerink Swann, William Blair, and Cowen and Company. Veracyte is a developer of molecular diagnostics tools aimed at cytology, used to analyze diseases using genetic sampling. The firm is backed by Domain Partners, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures.